Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting.
2 reports, 1 independent
Updated Aug 7
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Protagonist Therapeutics announced positive Phase 3 results for its peptide therapeutic Rusfertide for treating Polycythemia Vera.Sub-event
- Protagonist Therapeutics belongs to the biomedical and genetics industry sector.Sub-event
Protagonist Therapeutics made key submissions and presentations regarding its drug pipeline.1 source
- Protagonist Therapeutics announced co-development of Rusfertide and collaboration with Janssen Biotech on icotrokinra.
Keep exploring
The entities involved
- FDA
-
Protagonist Therapeutics (United States)
company in Milpitas, United States
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ACCESS NewswireProtagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to seve
- Unknown outlet